CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- 4 Planned sale Chief Operating Officer sold 7,097 shares at an average $18.03 ($127,938)
- 4 Planned sale Chief Scientific Officer sold 17,878 shares at an average $18.03 ($322,389)
- 4 Exercise or conversion Chief Financial Officer acquired 8,790 shares (option exercise)
- 4 Planned sale Chief Financial Officer sold 17,500 shares at an average $15.01 ($262,648)
- 4 Planned sale Chief Operating Officer sold 15,982 shares at an average $15.42 ($246,403)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale President and CEO sold 2,000 shares at $13.71 ($27,422)
- 4 Planned sale President and CEO sold 2,092 shares at $18.01 ($37,675)
- 4 Planned sale Chief Scientific Officer sold 3,961 shares at $18.00 ($71,316)
- 4/A Grant or award President and CEO acquired 49,650 shares (grant or award)
- 4/A Grant or award Chief Scientific Officer acquired 14,200 shares (grant or award)
- 4/A Grant or award Chief Financial Officer acquired 14,200 shares (grant or award)
- 4/A Grant or award Chief Medical Officer acquired 14,200 shares (grant or award)
- 4/A Grant or award Chief Operating Officer acquired 14,200 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Planned sale President and CEO sold 2,000 shares at an average $14.72 ($29,435)
Page 7 of 13 · 242 filings